Login to Your Account

Chemocentryx finds validation in $85M Vifor license

By Michael Fitzhugh
Staff Writer

Tuesday, May 10, 2016

In a coup for Chemocentryx Inc., Switzerland's Vifor Pharma Ltd. has agreed to pay $85 million in cash and equity to license commercial rights to CCX168, the company's complement 5a receptor inhibitor for orphan and rare renal diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription